rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DNLI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Denali Therapeutics at Jefferies Global Healthcare Conference: launch gains
      17h agoInvesting.comDNLIJEF
      Denali Therapeutics at UBS conference: launch momentum lifts outlook
      Nov 17Investing.comDNLIUBS
      Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)

      Analyst rates Denali (DNLI) stock a Buy. Avlayah's $17.8 million Q3 sales validate its platform, and Q4 guidance of $30-$32 million implies 65%+ sequential growth.

      Nov 13Seeking AlphaDNLI
      Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
      Nov 13Yahoo FinanceDNLI
      Wells Fargo initiates Denali Therapeutics stock with overweight rating
      Nov 13Investing.comDNLI
      Guggenheim reaffirms top pick in Biotech after Q3 results
      Nov 9Investing.comDNLI
      Is Denali Therapeutics (DNLI) Already Priced Right For Its Cash Flow?
      Nov 6Yahoo FinanceDNLI
      Denali Therapeutics (DNLI) Earnings Beat Puts Valuation Back In Focus
      Nov 6Yahoo FinanceDNLI
      Denali Therapeutics Inc (DNLI) Q3 2026 Earnings Call Highlights: AVLAYAH Revenue Soars Nearly ...

      Denali Therapeutics Inc (DNLI) beat Q3 revenue guidance on rapid payer coverage gains and faster patient transitions, guided Q4 to $30--32 million, and ended the quarter with $1.01 billion in cash.

      Nov 4Yahoo FinanceDNLI
      Why is Denali Therapeutics stock surging today?
      Nov 4Investing.comDNLI
      Denali Therapeutics Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceDNLI
      Denali Therapeutics Q3 2026 Earnings Call Transcript
      Nov 3BenzingaDNLI
      Denali Therapeutics soars on earnings beat
      Nov 3Yahoo FinanceDNLI
      Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates

      Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +7.25% and +41.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 3Yahoo FinanceDNLI
      Earnings call transcript: Denali Therapeutics tops Q3 2026 estimates, shares rise
      Nov 3Investing.comDNLI
      Wedbush Cuts Price Target on Denali Therapeutics to $23 From $27, Keeps Outperform Rating
      Oct 19Yahoo FinanceDNLI
      Denali Therapeutics Q2 2026 Earnings Call Transcript - Denali Therapeutics (NASDAQ:DNLI)

      On Thursday, Denali Therapeutics (NASDAQ:DNLI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call

      Oct 12BenzingaDNLI
      Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?
      Oct 10Yahoo FinanceDNLI
      6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards
      Sep 23Barron'sDNLIMS
      Denali Therapeutics at Morgan Stanley conference: launch momentum builds
      Sep 14Investing.comDNLIMS
      Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
      Sep 8Yahoo FinanceDNLIDYN
      Denali Therapeutics director sells $261,928 in stock
      Sep 5Investing.comDNLI
      B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating

      Denali Therapeutics (DNLI) has an average rating of buy and mean price target of $34.88, according t

      Aug 25Yahoo FinanceDNLI
      FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
      Aug 24ReutersDNLI

      This is the newest page. Registered accounts read further back.